Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting

GlobeNewswire April 28, 2021

Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel

GlobeNewswire April 12, 2021

Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting

GlobeNewswire April 12, 2021

Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 18, 2021

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 11, 2021

Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update

GlobeNewswire March 4, 2021

Oncternal Therapeutics to Participate in March Investor Conferences

GlobeNewswire February 24, 2021

Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 22, 2021

Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors

GlobeNewswire January 28, 2021

Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

GlobeNewswire January 14, 2021

Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

GlobeNewswire January 7, 2021

Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

GlobeNewswire January 5, 2021

Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire December 14, 2020

Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering

GlobeNewswire December 9, 2020

Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting

GlobeNewswire December 7, 2020

Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting

GlobeNewswire November 11, 2020

Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference

GlobeNewswire November 9, 2020

Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 4, 2020

Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma

Business Wire October 6, 2020

Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments

PR Newswire September 22, 2020